We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
+29.88%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
+$38.4M
(+29%)
Cap. Flow
+$19.7M
Cap. Flow
% of AUM
11.56%
Top 10 Holdings %
Top 10 Hldgs %
54.57%
Holding
80
New
11
Increased
19
Reduced
14
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$6.27M |
| 2 |
Intellia Therapeutics
NTLA
|
+$3.52M |
| 3 |
Compass Therapeutics
CMPX
|
+$3.32M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$2.28M |
| 5 |
Solid Biosciences
SLDB
|
+$2.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axogen
AXGN
|
+$2.12M |
| 2 |
Inhibrx
INBX
|
+$1.91M |
| 3 |
uniQure
QURE
|
+$1.85M |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
+$1.16M |
| 5 |
Prothena Corp
PRTA
|
+$1.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.96% |
| 2 | Technology | 19.61% |
| 3 | Energy | 3.55% |
| 4 | Materials | 0.54% |
| 5 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Treace Medical Concepts
TMCI
$274M
| $556K | 0.33% |
226,947
+50,000
| +28% | +$217K |
|
52
Pulmonx
LUNG
$57.4M
| $554K | 0.32% |
+250,573
| New | +$471K |
|
|
RAPT
53
DELISTED
RAPT Therapeutics
RAPT
| $508K | 0.3% |
+15,000
| New | +$466K |
|
54
Gossamer Bio
GOSS
$71.8M
| $428K | 0.25% |
138,176
| – | – |
|
55
Alphatec Holdings
ATEC
$1.29B
| $380K | 0.22% |
18,058
-14,942
| -45% | -$277K |
|
56
Outset Medical
OM
$75.8M
| $367K | 0.21% |
98,913
+20,329
| +26% | +$174K |
|
|
APLS
57
DELISTED
Apellis Pharmaceuticals
APLS
| $352K | 0.21% |
14,000
| – | – |
|
58
Liquidia Corp
LQDA
$6.98B
| $345K | 0.2% |
+10,000
| New | +$285K |
|
59
Candel Therapeutics
CADL
$719M
| $339K | 0.2% |
60,000
| – | – |
|
60
Voyager Therapeutics
VYGR
$187M
| $294K | 0.17% |
74,918
-60,000
| -44% | -$265K |
|
61
Trinity Capital
TRIN
$1.57B
| $293K | 0.17% |
+20,000
| New | +$298K |
|
|
62
Inhibrx
INBX
$1.26B
| $292K | 0.17% |
3,698
-28,000
| -88% | -$1.91M |
|
|
KBDC
63
Kayne Anderson BDC
KBDC
$891M
| $286K | 0.17% |
+20,000
| New | +$291K |
|
64
Cullinan Oncology
CGEM
$1.09B
| $207K | 0.12% |
20,000
| – | – |
|
65
Elutia
ELUT
$42M
| $182K | 0.11% |
263,018
-448,157
| -63% | -$340K |
|
|
ALMS
66
Alumis Inc
ALMS
$3.63B
| $97.6K | 0.06% |
10,000
| – | – |
|
67
DocGo
DCGO
$67.5M
| $43.8K | 0.03% |
49,908
-714,154
| -93% | -$763K |
|
68
Zentalis Pharmaceuticals
ZNTL
$373M
| $22.9K | 0.01% |
17,000
| – | – |
|
|
APLT
69
DELISTED
Applied Therapeutics
APLT
| – | – |
-225,000
| Closed | -$136K |
|
70
Avalo Therapeutics
AVTX
$985M
| – | – |
-31,000
| Closed | -$394K |
|
|
71
Axogen
AXGN
$2.09B
| – | – |
-119,078
| Closed | -$2.12M |
|
72
Guardant Health
GH
$19.9B
| – | – |
-6,000
| Closed | -$375K |
|
73
InflaRx
IFRX
$272M
| – | – |
-50,000
| Closed | -$67K |
|
74
OrthoPediatrics
KIDS
$501M
| – | – |
-16,000
| Closed | -$296K |
|
|
75
Kiniksa Pharmaceuticals
KNSA
$4.84B
| – | – |
-30,000
| Closed | -$1.16M |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q4 2025 Portfolio in Review
As of Q4 2025, Birchview Capital held 80 positions worth $171M, up 29% from $132M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Birchview Capital deployed $19.7M of net new capital in Q4 2025, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Lam Research: 40,329 shares worth $6.9M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Inhibrx, an estimated $1.91M trimmed.
- Birchview Capital's largest Q4 2025 buy was Lam Research: 40,329 shares worth $6.9M.
- Birchview Capital added most to Intellia Therapeutics in Q4 2025, an estimated $3.52M increase.
- Birchview Capital's biggest Q4 2025 reduction was Inhibrx, cutting an estimated $1.91M.
- Birchview Capital fully exited Axogen in Q4 2025, selling an estimated $2.12M.
- Birchview Capital's ten largest holdings make up 55% of its $171M portfolio in Q4 2025.
- Birchview Capital opened 11 new positions and closed 12 in Q4 2025.
- Birchview Capital's portfolio value rose 29% quarter-over-quarter to $171M.
Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.